Search for 'Provider:Journal of Hypertension, and au:Ruilope Urioste, Luis Miguel'

Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance.

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Journal of hypertension, 2013 . 31(1):103-8. , Formato Vancouver: Oliveras A, García-Ortiz L, Segura J, Banegas JR, Martell-Claros N, Vigil L et al. PRESCEN Study, Spain. Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. J Hypertens. 2013 Jan;31(1):103-8.

Place Hold on Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance.

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2013 . 31(10):1925-38. , Formato Vancouver: ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013 Oct;31(10):1925-38.

Place Hold on 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.

European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2013 . 31(9):1731-68. , Formato Vancouver: O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013 Sep;31(9):1731-68.

Place Hold on European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring.

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension

By Ruilope Urioste, Luis Miguel. Journal of Hypertension, 2012 . 30(4):811-818 , Formato Vancouver: Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, et al. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012;30(4):811-8.

Place Hold on Prevention of microalbuminuria in patients with type 2 diabetes and hypertension

Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?

By Ruilope Urioste, Luis Miguel. Journal of Hypertension, 2012 . 30(4):647-654. , Formato Vancouver: Volpe M, Danser AH, Menard J, Waeber B, Mueller DN, Maggioni AP, et al. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum? J Hypertens. 2012;30(4):647-54.

Place Hold on Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?

Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study.

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Journal of Hypertension, 2012 . 30(4):713-9. , Formato Vancouver: de la Sierra A, Banegas JR, Segura J, Gorostidi M, Ruilope LM; CARDIORISC Event Investigators.. Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study. J Hypertens. 2012 Apr;30(4):713-9.

Place Hold on Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study.

Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression.

By Cerezo Olmos, César | García Donaire, José Antonio | Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Journal of Hypertension, 2012 . 30(1):204-9. , Formato Vancouver: Cerezo C, Ruilope LM, Segura J, García-Donaire JA, de la Cruz JJ, Banegas JR, et al. Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens. 2012 Jan;30(1):204-9.

Place Hold on Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression.

Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Journal of Hypertension, 2012 . 30(6):1211-1216. , Formato Vancouver: de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens. 2012;30(6):1211-6.

Place Hold on Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs

ESH position paper: renal denervation - an interventional therapy of resistant hypertension.

By Ruilope Urioste, Luis Miguel. Journal of Hypertension, 2012 . 30(5):837-41. , Formato Vancouver: Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012 May;30(5):837-41.

Place Hold on ESH position paper: renal denervation - an interventional therapy of resistant hypertension.

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

By Ruilope Urioste, Luis Miguel. Journal of Hypertension, 2011 . 29(5):980-990. , Formato Vancouver: Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980-90.

Place Hold on A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

Blood pressure control by the nifedipine GITS–telmisartan combination in patients at high cardiovascular risk: the TALENT study

By Ruilope Urioste, Luis Miguel. Journal of Hypertension, 2011 . 29(3):600-609. , Formato Vancouver: Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM; TALENT investigators. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens. 2011 Mar;29(3):600-9.

Place Hold on Blood pressure control by the nifedipine GITS–telmisartan combination in patients at high cardiovascular risk: the TALENT study

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Journal of hypertension, 2014 . 32(9):1888-97. , Formato Vancouver: Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens. 2014 Sep;32(9):1888-97.

Place Hold on Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.

Can we make an adequate estimation of urinary sodium excretion avoiding 24-h urine collection?.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(5):977. , Formato Vancouver: Ruilope LM. Can we make an adequate estimation of urinary sodium excretion avoiding 24-h urine collection? J Hypertens. 2014 May;32(5):977.

Place Hold on Can we make an adequate estimation of urinary sodium excretion avoiding 24-h urine collection?.

Reply: contribution of the ABP-International study to the definition of night-time tachycardia.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(10):2101. , Formato Vancouver: Vinyoles E, Sierra Ade L, Roso A, Cruz JJ, Gorostidi M, Segura J et al; Spanish ABPM Registry of Investigators. Reply: contribution of the ABP-International study to the definition of night-time tachycardia. J Hypertens. 2014 Oct;32(10):2101.

Place Hold on Reply: contribution of the ABP-International study to the definition of night-time tachycardia.

Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.

By Ruiz Hurtado, Gema | Pulido Olmo, Helena | Cerezo Olmos, César | Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel | Praga Terente, Manuel. Journal of hypertension, 2014 . 32(10):2082-91; discussion 2091. , Formato Vancouver: Ruiz-Hurtado G, Condezo-Hoyos L, Pulido-Olmo H, Aranguez I, Del Carmen Gónzalez M, Arribas S et al. Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. J Hypertens. 2014 Oct;32(10):2082-91; discussion 2091.

Place Hold on Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.

Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(10):1970-8. , Formato Vancouver: Sánchez-Chaparro MA, Calvo-Bonacho E, González-Quintela A, Cabrera M, Quevedo-Aguado L, Fernández-Labandera C et al; ICARIA (Ibermutuamur CArdiovascular RIsk Assessment) Study Group. Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors. J Hypertens. 2014 Oct;32(10):1970-8.

Place Hold on Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors.

Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(5):1016-24. , Formato Vancouver: Vinyoles E, de la Sierra A, Roso A, de la Cruz JJ, Gorostidi M, Segura J et al; Spanish ABPM Registry investigators. Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry. J Hypertens. 2014 May;32(5):1016-24.

Place Hold on Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry.

Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. American journal of hypertension, 2014 . 27(5):680-7. , Formato Vancouver: De la Sierra A, Gorostidi M, Banegas JR, Segura J, de la Cruz JJ, Ruilope LM. Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?. Am J Hypertens. 2014 May;27(5):680-7.

Place Hold on Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?.

Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(11):2267-76; discussion 2276. , Formato Vancouver: Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE. Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. J Hypertens. 2014 Nov;32(11):2267-76; discussion 2276.

Place Hold on Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.

LCZ696, The Need for an Indication in Arterial Hypertension.

By Prado, José C | Ruilope Urioste, Luis Miguel. American journal of hypertension, 2015 . 28(12):1403-4. , Formato Vancouver: Prado JC, Ruilope LM. LCZ696, The Need for an Indication in Arterial Hypertension. Am J Hypertens. 2015 Dec;28(12):1403-4.

Place Hold on LCZ696, The Need for an Indication in Arterial Hypertension.

Salutary cardiovascular effects of antidiabetic drugs: myth or fact?.

By Ruiz Hurtado, Gema | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2015 . 33(11):2198-9. , Formato Vancouver: Ruiz Hurtado G, Ruilope LM. Salutary cardiovascular effects of antidiabetic drugs: myth or fact? J Hypertens. 2015 Nov;33(11):2198-9.

Place Hold on Salutary cardiovascular effects of antidiabetic drugs: myth or fact?.

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

By Rodicio Díaz, José Luis | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2016 . 34(3):393-6. , Formato Vancouver: Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba Badiale M et al; ESH-CHL-SHOT trial investigators. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016 Mar;34(3):393-6.

Place Hold on Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.